Elevance Health, Inc. $ELV Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. raised its stake in Elevance Health, Inc. (NYSE:ELV) by 48.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,400 shares of the company’s stock after buying an additional 2,748 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Elevance Health were worth $2,796,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vermillion & White Wealth Management Group LLC increased its stake in Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health in the second quarter valued at $32,000. Motco increased its position in shares of Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. True Wealth Design LLC increased its position in shares of Elevance Health by 431.8% in the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares in the last quarter. Finally, Glass Jacobson Investment Advisors llc raised its stake in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock worth $39,000 after buying an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Stock Down 0.4%

ELV stock opened at $345.62 on Friday. The company has a 50 day moving average price of $351.69 and a two-hundred day moving average price of $328.98. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The stock has a market capitalization of $76.81 billion, a P/E ratio of 13.76, a PEG ratio of 1.88 and a beta of 0.51. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ELV shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research note on Thursday. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Robert W. Baird raised their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Wells Fargo & Company reduced their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $396.90.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.